A Gene Expression and Pre-mRNA Splicing Signature That Marks the Adenoma-Adenocarcinoma Progression in Colorectal Cancer

被引:50
作者
Pesson, Marine [1 ]
Volant, Alain [1 ,2 ]
Uguen, Arnaud [1 ,2 ]
Trillet, Kilian [1 ]
De La Grange, Pierre [3 ]
Aubry, Marc [4 ]
Daoulas, Melanie [2 ]
Robaszkiewicz, Michel [2 ]
Le Gac, Gerald [1 ,2 ]
Morel, Alain [5 ]
Simon, Brigitte [1 ]
Corcos, Laurent [1 ,2 ]
机构
[1] Univ Bretagne Occidentale, INSERM, UMR 1078, Struct Federat Rech ScInBioS,Fac Med, Brest, France
[2] Ctr Hosp Reg Univ Brest, Brest, France
[3] Hop St Louis, Inst Univ Hematol, Ctr Hayem, GenoSplice Technol, Paris, France
[4] Univ Rennes 1, CNRS, UMR 6290, Lab Genom Med,Inst Genet & Dev Rennes,Unite Mixte, Rennes, France
[5] Ctr Paul Papin, INSERM, UMR 892, Inst Rech Canc Nantes Atlantique, Angers, France
关键词
COLON-CANCER; IDENTIFICATION; OVEREXPRESSION; POLYPECTOMY; MICROARRAY; ENRICHMENT; MORPHOLOGY; BIOMARKERS; INHIBITOR; DIAGNOSIS;
D O I
10.1371/journal.pone.0087761
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
It is widely accepted that most colorectal cancers (CRCs) arise from colorectal adenomas (CRAs), but transcriptomic data characterizing the progression from colorectal normal mucosa to adenoma, and then to adenocarcinoma are scarce. These transition steps were investigated using microarrays, both at the level of gene expression and alternative pre-mRNA splicing. Many genes and exons were abnormally expressed in CRAs, even more than in CRCs, as compared to normal mucosae. Known biological pathways involved in CRC were altered in CRA, but several new enriched pathways were also recognized, such as the complement and coagulation cascades. We also identified four intersectional transcriptional signatures that could distinguish CRAs from normal mucosae or CRCs, including a signature of 40 genes differentially deregulated in both CRA and CRC samples. A majority of these genes had been described in different cancers, including FBLN1 or INHBA, but only a few in CRC. Several of these changes were also observed at the protein level. In addition, 20% of these genes (i.e. CFH, CRYAB, DPT, FBLN1, ITIH5, NR3C2, SLIT3 and TIMP1) showed altered pre-mRNA splicing in CRAs. As a global variation occurring since the CRA stage, and maintained in CRC, the expression and splicing changes of this 40-gene set may mark the risk of cancer occurrence from analysis of CRA biopsies.
引用
收藏
页数:13
相关论文
共 53 条
[31]  
Khamas A, 2012, CANCER GENOM PROTEOM, V9, P67
[32]   Overexpression and β-1,6-N-Acetylglucosaminylation-initiated Aberrant Glycosylation of TIMP-1 A "DOUBLE WHAMMY" STRATEGY IN COLON CANCER PROGRESSION [J].
Kim, Yong-Sam ;
Ahn, Yeong Hee ;
Song, Kyoung Jin ;
Kang, Jeong Gu ;
Lee, Ju Hee ;
Jeon, Seong Kook ;
Kim, Hyoung-Chin ;
Yoo, Jong Shin ;
Ko, Jeong-Heon .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (39) :32467-32478
[33]   Aurora kinase expression in colorectal adenocarcinoma: correlations with clinicopathological features, p16 expression, and telomerase activity [J].
Lam, Alfred King-Yin ;
Ong, Kate ;
Ho, Yik-Hong .
HUMAN PATHOLOGY, 2008, 39 (04) :599-604
[34]   Consensus Pathways Implicated in Prognosis of Colorectal Cancer Identified Through Systematic Enrichment Analysis of Gene Expression Profiling Studies [J].
Lascorz, Jesus ;
Chen, Bowang ;
Hemminki, Kari ;
Forsti, Asta .
PLOS ONE, 2011, 6 (04)
[35]   Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomas [J].
Lin, YM ;
Furukawa, Y ;
Tsunoda, T ;
Yue, CT ;
Yang, KC ;
Nakamura, Y .
ONCOGENE, 2002, 21 (26) :4120-4128
[36]   Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method [J].
Livak, KJ ;
Schmittgen, TD .
METHODS, 2001, 25 (04) :402-408
[37]   Candidate microRNA biomarkers in human colorectal cancer: Systematic review profiling studies and experimental validation [J].
Ma, Yanlei ;
Zhang, Peng ;
Yang, Jianjun ;
Liu, Zhihua ;
Yang, Zhe ;
Qin, Huanlong .
INTERNATIONAL JOURNAL OF CANCER, 2012, 130 (09) :2077-2087
[38]   Abnormal expression of TRIB3 in colorectal cancer: a novel marker for prognosis [J].
Miyoshi, N. ;
Ishii, H. ;
Mimori, K. ;
Takatsuno, Y. ;
Kim, H. ;
Hirose, H. ;
Sekimoto, M. ;
Doki, Y. ;
Mori, M. .
BRITISH JOURNAL OF CANCER, 2009, 101 (10) :1664-1670
[39]   RGS16 Is a Marker for Prognosis in Colorectal Cancer [J].
Miyoshi, Norikatsu ;
Ishii, Hideshi ;
Sekimoto, Mitsugu ;
Doki, Yuichiro ;
Mori, Masaki .
ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (12) :3507-3514
[40]  
Pal S., 2012, Pharmacology therapeutics